Shares of Nano-X Imaging (NASDAQ: NNOX) are down about 53% over the past 12 months, and it's not hard to understand why. The company generated a lot of buzz when it earned Food and Drug Administration (FDA) clearance to market the Nanox.ARC a little over a year ago, but sales haven't grown.

Nanox.ARC's U.S. launch isn't proceeding as quickly as investors had hoped, but some investors were encouraged by one of its investors. In February, Nvidia (NASDAQ: NVDA) disclosed that it has 59,632 shares of Nano-X stock in its portfolio.

Is Nano-X a good stock to buy on the dip? Here's what you should know before taking a chance on this stock.

Continue reading

Source Fool.com